Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging

Sha Lou, Benjamin Balluff, Arjen H. G. Cleven, Judith V. M. G. Bovee, Liam A. McDonnell*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Web of Science)

Abstract

Metabolites can be an important read-out of disease. The identification and validation of biomarkers in the cancer metabolome that can stratify high-risk patients is one of the main current research aspects. Mass spectrometry has become the technique of choice for metabolomics studies, and mass spectrometry imaging (MSI) enables their visualization in patient tissues. In this study, we used MSI to identify prognostic metabolite biomarkers in high grade sarcomas; 33 high grade sarcoma patients, comprising osteosarcoma, leiomyosarcoma, myxofibrosarcoma, and undifferentiated pleomorphic sarcoma were analyzed. Metabolite MSI data were obtained from sections of fresh frozen tissue specimens with matrix-assisted laser/desorption ionization (MALDI) MSI in negative polarity using 9-aminoarcridine as matrix. Subsequent annotation of tumor regions by expert pathologists resulted in tumor-specific metabolite signatures, which were then tested for association with patient survival. Metabolite signals with significant clinical value were further validated and identified by high mass resolution Fourier transform ion cyclotron resonance (FTICR) MSI. Three metabolite signals were found to correlate with overall survival (m/z 180.9436 and 241.0118) and metastasis-free survival (m/z 160.8417). FTICR-MSI identified m/z 241.0118 as inositol cyclic phosphate and m/z 160.8417 as carnitine.

Original languageEnglish
Pages (from-to)376-383
Number of pages8
JournalJournal of the American Society for Mass Spectrometry
Volume28
Issue number2
DOIs
Publication statusPublished - Feb 2017

Keywords

  • Metabolites
  • Prognosis
  • Biomarker discovery
  • MALDI-MSI
  • High grade sarcoma
  • Leiomyosarcoma
  • Myxofibrosarcoma
  • Osteosarcoma
  • Undifferentiated pleomorphic sarcoma
  • Soft tissue sarcoma
  • THERAPEUTIC TARGETS
  • CURRENT STATE
  • CANCER-CELLS
  • MS
  • METABOLOMICS
  • VISUALIZATION
  • DIAGNOSIS
  • HISTOLOGY
  • TUMORS
  • GRADE

Cite this